AbCellera Biologics(ABCL) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue for the year was $75 million, a significant increase from approximately $29 million in 2024, with $36 million stemming from settling patent infringement claims against Bruker [13][14] - The net loss for the year was roughly $146 million, an improvement compared to a loss of about $163 million in the previous year, resulting in a loss of $0.49 per share [14] - Operating activities used approximately $130 million in cash and equivalents for the year [14][16] Business Line Data and Key Metrics Changes - The company initiated work on one additional partner-initiated program, bringing the cumulative total to 104 programs with downstream participation [10] - The focus on proprietary pipeline advancement led to a decision to stop reporting on partner-initiated program starts on a quarterly basis starting in 2026 [10] Market Data and Key Metrics Changes - The company has approximately $700 million in available liquidity, including $560 million in cash and equivalents and $140 million in committed government funding [10][16] - The clinical pipeline includes 19 molecules that have reached the clinic, with ABCL635 advancing into a Phase 2 study [11][12] Company Strategy and Development Direction - The company aims to become a vertically integrated clinical-stage biotech, having successfully transitioned from building its platform to focusing on pipeline development [4][5] - Key priorities for 2026 include delivering top-line readouts for ABCL635 Phase 2 and ABCL575 Phase 1 studies, advancing ABCL688 and ABCL386 through IND-enabling activities, and adding one new development candidate [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of ABCL635, with a positive Phase 2 readout expected to lead to late-stage development [8][9] - The company acknowledges the uncertainties in drug development but remains committed to advancing its pipeline and believes it has sufficient liquidity to fund operations beyond the next three years [17] Other Important Information - The company has made significant investments in property, plant, and equipment to establish clinical manufacturing capabilities, which are now substantially complete [15] - The clinical manufacturing facility allows for better control of the supply chain and improved flexibility [15] Q&A Session Summary Question: Potential for ABCL575 as a combination regimen - Management believes in the potential of OX40 ligand as a class and is exploring combination opportunities internally and with external parties [21][22] Question: Oncology-based BMS studies - Management sees opportunities in breast and prostate cancer, particularly for patients experiencing severe hot flashes [26] - Differentiation in safety and convenience is viewed as a major factor in the product profile [27] Question: Update on ABCL635 target engagement data - The Phase I portion of the study will be released alongside the Phase II data in Q3, with no announcements expected before then [32] Question: Clinical trial infrastructure capacity - The company has reshaped its internal resources to support multiple programs in clinical development and is committed to building operational capacity [43][44] Question: Decision factors for ABCL575 development - The decision will largely depend on external factors, including partnership opportunities and the competitive landscape [45]